Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested
May 18, 2015
Brenda Sanburg
The Pink Sheet
Axinn Counsel Stacie Ropka was quoted in The Pink Sheet’s article, “Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested." The Pink Sheet is produced by Pharma & Med Tech Business Intelligence.
Click here to access the article. A subscription is required.